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approved WNV IgM tests, we were
concerned that this phenomenon
might also occur with new tests. Thus
in 2004, we initiated a follow-up
study of patients infected during the
inaugural (2003) WNV season in
Alberta, Canada.
Fifty patients who were WNV IgM
positive by 2 commercial IgM kits
(West Nile virus capture EIAs, Focus
Technologies, Cypress, CA, USA,
and Panbio, Windsor, Queensland,
Australia) during the fall of 2003 were
contacted. Sera were recollected and
tested for IgM and IgG antibodies to
WNV with current kits from these 2
companies. Sera were also tested for
hemagglutination-inhibiting (HI) anti-
bodies to WNV (2).
Of 39 serum samples from 38
patients, 28 were positive, 5 were inde-
terminate, and 6 were negative with
the Focus IgM kit. Twenty-one were
positive, 3 were indeterminate, and 14
were negative with the Panbio IgM kit.
All had WNV IgG antibodies detected
by Focus and Panbio IgG kits. We
detected HI antibodies to WNV in all
patients, and titers in 12 were >320.
The time course for IgM index values
for the Focus IgM kit used in 2003 and
2004 is shown in the Figure.
These data show that when tests are
conducted with newly available kits,
as with the CDC in-house test, IgM
antibody to WNV persists for ≥8
months in most patients. A single high
HI titer is not helpful in identifying
recent infection. In addition, the IgM
test cannot differentiate between
recent and past infections. Interpreting
a positive IgM result in WNV-endem-
ic areas will be complex because a
positive WNV IgM result could indi-
cate a current acute infection or a pre-
vious WNV infection even in a person
with a different acute illness.
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Hepatitis A, Italy
To the Editor: Hepatitis A virus
(HAV) infection rates are very low in
industrialized countries. A noticeable
fall in the prevalence of HAV antibod-
ies (anti-HAV) has been reported in
southern European and Mediterranean
countries such as Spain (1) and
Greece (2), reflecting improvements
in hygiene standards in the last
decades.
An HAV prevalence of 66.3% in
1981 (3) and 29.4% in 1990 (4) was
shown in studies conducted in mili-
tary recruits from all Italian regions.
In both studies, subjects from south-
ern regions had a higher HAV preva-
lence than those from north-central
regions. In 2003, we conducted a
study of recruits to show changes in
HAV infection prevalence in younger
Italian generations.
Military service was compulsory
in Italy at that time; all men 18–26
years of age were included. From
September to December 2003, 323
recruits 18–26 years of age (mean age
20 years), representing all Italian
regions, who had been accepted for
Air Force military service were tested
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Figure. West Nile virus (WNV) immunoglobulin (Ig)M index values in serum specimens
from 38 WNV case-patients detected in the fall of 2003. The assay was performed by
using the Focus Technologies kit, as per the manufacturer’s instructions. An index >1.1
indicates a positive result and an index <0.9 indicates a negative result.
LETTERS
for anti-HAV in the recruitment center
at Viterbo. This recruitment center,
used in the 1990 study, was chosen
again because it is located near Rome
and adherence to protocol was easier
to control. 
A standard, precoded question-
naire was designed to collect informa-
tion in the same sequence as questions
asked by military personnel during
the examination. The same informa-
tion was collected as in the previous
studies: date of birth, residence,
father’s years of education, and fami-
ly size. After informed consent was
obtained, blood samples were collect-
ed and stored at –30°C until tested.
No person was vaccinated against
HAV. Anti-HAV assay was performed
by using commercial immunoenzy-
matic method (Abbot Laboratories,
North Chicago, IL, USA). The meth-
ods used in the 1981 and 1990 studies
have similar sensitivity and specifici-
ty between them and in relation to that
used in the current study, and are
detailed elsewhere (3,4).
The prevalence of anti-HAV
declined from 66.3% in 1981 to 5.3%
in 2003 (p<0.01, χ2 test). In 2003, the
prevalence was 2.1 % in the north-
central region and 7.9% in southern
regions (Figure). However, southern
residents were more likely to have
been exposed to HAV than north-cen-
tral residents (p<0.02, χ2 test). No
statistical difference relative to
father’s years of education or family
size was shown. Basic requirements
for Navy (1981 study) and Air Force
(1990 and 2003 studies) enrollment
were similar. Thus, the 3 studies are
comparable and a valid estimation of
epidemiologic changes over time.
The anti-HAV prevalence shown
in this study (5.3%) indicates that
Italy has very low endemicity of HAV
infection, at least in the young male
population. The decline of HAV infec-
tion for >20 years is a consequence of
good sanitation and hygienic condi-
tions (vaccination against HAV is
rarely performed in Italy) and has
generated an increasing proportion of
adults who are susceptible to this
virus at an age characterized by the
likely occurrence of a more severe
clinical illness (5). This situation will
likely necessitate costly interventions,
such as vaccinating risk groups (e.g.,
military personnel, healthcare work-
ers), to prevent HAV infection. Thus,
HAV vaccination has been included in
the compulsory vaccination schedule
of the Italian military personnel since
1998 (6).
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Figure. Anti-hepatitis A virus prevalence, 1981–2003
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